Clinical Trials Logo

Shock clinical trials

View clinical trials related to Shock.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06398262 Not yet recruiting - Oxygen Clinical Trials

Alar SpO2 Sensor Study

Start date: April 22, 2024
Phase:
Study type: Observational

BACKGROUND: As the normal functioning of the body is dependent on oxygen, low blood oxygenation is a acute problem that needs immediate attention. Measurement of blood oxygenation is therefore central to monitor patients and is usually done using light technology with a clip on the finger. Philips manufactures a measuring clip that is designed to measure oxygenation in the nasal wing instead of the finger. The advantage of this is that the nose is not affected as much as the fingers by poor blood flow in the skin, for example caused by cold. The nose is also closer to the heart and lungs than the hand, so changes in oxygenation may be detected earlier. This newer meter is an approved CE-marked product that is available for clinical use, but the next step is to investigate it systematically during and after surgery.

NCT ID: NCT06384287 Not yet recruiting - Clinical trials for Acute Circulatory Failure

Peripheral Tissue Perfusion in Intensive Care

INPPEREA
Start date: April 2024
Phase:
Study type: Observational

Tissue perfusion has been identified as an early prognosis factor in patients admitted to intensive care. However, little is known about the effects of different hemodynamic interventions performed in clinical routine on peripheral tissue perfusion. The aim of this work is to study the kinetics of CRT and local skin blood flow following therapeutic intervention (fluid challenge, vasopressor or inotropic drug).

NCT ID: NCT06372106 Not yet recruiting - Oxygen Clinical Trials

Project Mountain - Comparing SpO2 and SaO2 for Accuracy

Start date: April 2024
Phase:
Study type: Observational

The main goal of this study is to look at the performance of the neonatal, infant, and pediatric Philips SpO2 sensors with the Philips FAST Pulse Oximetry technology. Oxygen saturation measurements (SpO2) will be obtained via pulse oximetry and invasive arterial oxygen measurements (SaO2) will be obtained via arterial blood samples as part of your clinical care and assessed by co-oximetry. The study will aim to enroll a diverse population to help us understand the impact of skin pigmentation.

NCT ID: NCT06371677 Not yet recruiting - Stroke Clinical Trials

Polish Nationwide Register of Hospitalized Patients in Cardiac Intensive Care Units

POL-CICU
Start date: October 1, 2024
Phase:
Study type: Observational [Patient Registry]

Cardiac Intensive Care Units (CICUs) provide care for a diverse patient population. Understanding the clinical characteristics, analysis of treatment modalities, and prognosis of patients hospitalized in the CICU are important to improve cardiovascular care. The purpose of this registry is to determine the demographics, clinical, treatment, and prognosis of patients hospitalized in the Polish CICUs. Data from this multicenter, prospective observational study will provide more robust data to facilitate quantitative characterization of cardiac care in contemporary Polish CICUs and enable the development of infrastructure for clinical trials in CICUs.

NCT ID: NCT06369818 Not yet recruiting - Cardiogenic Shock Clinical Trials

Correlation of Cardiac Output Determined by Echocardiography and Indirect Calorimetry in Critically Ill Patients in Cardiogenic Shock on Extracorporeal Circulatory Life Support

Start date: April 2024
Phase:
Study type: Observational

This observational study investigates whether the daily measured trend of cardiac output as evaluated by indirect calorimetry correlates with the same evaluated by transthoracic echocardiography.

NCT ID: NCT06366854 Not yet recruiting - Septic Shock Clinical Trials

UK ANDROMEDA-Shock-2 RCT

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The purpose of the trial is to test if a strategy of resuscitation guided by capillary refill time and individualised clinical hemodynamic phenotyping can improve important clinical outcomes within 28 days in septic shock patients compared to usual care.

NCT ID: NCT06351150 Not yet recruiting - Vasodilatory Shock Clinical Trials

Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock

Start date: May 2024
Phase: Phase 3
Study type: Interventional

A randomized, double-blind, placebo-controlled study on the treatment of refractory distributed shock with angiotensin II injection, with a random ratio of 1:1. Assuming a success rate of 25% for the main therapeutic endpoint in the control group and 50% for the experimental group, a total of 214 subjects will be enrolled, including 107 in the experimental group and 107 in the control group.

NCT ID: NCT06343519 Not yet recruiting - Shock Clinical Trials

Echocardiographic and Laboratory Findings in Hemodynamic Monitoring of Shocked Patients

Start date: May 2024
Phase:
Study type: Observational

Shocked patients require prompt and accurate assessment of their hemodynamic status to guide appropriate management. Echocardiography is a valuable tool for assessing cardiac function, while laboratory parameters such as mixed venous oxygen saturation and arterial blood lactate provide insights into tissue perfusion and oxygen metabolism. This study aims to compare echocardiographic findings, including cardiac index, speckle tracking parameters, and tissue Doppler indices, with laboratory findings in the evaluation of hemodynamic monitoring in shocked patients.

NCT ID: NCT06306001 Not yet recruiting - Neonatal Sepsis Clinical Trials

Intravenous Methylene Blue for Treating Refractory Neonatal Septic Shock

Start date: March 15, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Preterm infants (born at less than 37 weeks of pregnancy) sometimes develop a serious blood infection leading to low blood pressure, which does not respond to saline or to the standard medicines for increasing blood pressure, such as dopamine and epinephrine. The goal of this research study is to compare the effect of giving an injectable medicine called Methylene blue (MB) versus not giving MB to such preterm infants who are unresponsive to standard treatment. The main questions that this study aims to answer is: 1. Whether MB treatment reduces death to any cause as compared to no MB treatment. 2. Whether treatment with MB reduces the time to achieve normal blood pressure 3. Whether treatment with MB reduces the time to stoppage of all blood pressure medications, steroids and normal saline. 4. Whether treatment with MB improves heart function as measured by echocardiography at 24 and 48 hours.

NCT ID: NCT06302998 Not yet recruiting - Sepsis Clinical Trials

Dexmedetomidine and Vasopressin in Septic Shock

DecatSepsis-2
Start date: June 2024
Phase: Phase 2
Study type: Interventional

Rudiger and Singer suggested strategies for refining adrenergic stress (decatecholaminization). They proposed the use of dexmedetomidine and vasopressin to reduce the catecholamine load during sepsis. The investigators will use vasopressin as the primary vasopressor and a heart rate-calibrated dexmedetomidine infusion in septic shock patients. The investigators of the current study will use DEXPRESSIN in septic shock patients to investigate the effects of decatecholaminization on in-hospital mortality.